Immunologic Endpoints Against Young Infant Group B Streptococcal Disease

Program Description: To provide a case-control study comparing naturally occurring group B strep antibodies in young infants with invasive disease versus controls will establish antibody thresholds associated with protection and inform decisions about future maternal Group B Streptococcus vaccine licensure.
Funding Partners:
  • Bill & Melinda Gates Foundation
Program Partners:
  • CDC's National Center for Immunization and Respiratory Diseases
Program Location:
  • United States of America